Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE launches $250 million fund for device investments

This article was originally published in The Gray Sheet

Executive Summary

GE Healthcare plans to invest $250 million in "high potential" health care technology companies through its GE Healthymagination Fund, launched Oct. 21. A component of the firm's recently unveiled Healthymagination initiative, a global commitment "to deliver better health care to more people at lower cost," the equity investment fund will target three broad areas for investment: diagnostics, health care information technology and life sciences, according to the company (1"The Gray Sheet" May 11, 2009)

You may also be interested in...



GE’s ‘Healthymagination’ Campaign Reflects New Focus On Low Cost Products

GE will shift more of its health care R&D spending toward lower-priced medical products over the next six years under an initiative announced May 7

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel